Competing interests: The BMJ has judged that there were no disqualifying financial ties to commercial companies at the time of commissioning and writing the article (https://www.bmj.com/sites/default/files/attachments/resources/2016/03/16-current-bmj-education-coi-form.pdf). The authors declare the following other interests two years after commissioning and submission of the first draft: RS is a co-investigator for phase 3 randomised clinical trials on treatment of atrial fibrillation, acute coronary syndromes, and LDL cholesterol lowering (Librexis-ACS, Librexia-AF, and Victorion trials).